Breast Biomarker Testing, and What To Do With HER2

Course overview

Breast biomarker testing has been a routine and standardized part of pathology practice for many decades. With the advent of precision medicine and the introduction of more companion diagnostic assays to guide patient management, pathology laboratories have had to optimize and validate new assays with increasing frequency, often with assay indications evolving during the process. Pathologists, now more than ever, are essential to the patient management team and need to be able to speak to the role of breast biomarker testing as it pertains to treatment decision-making. After this presentation, participants will be able to: - Review the current ASCO/CAP biomarker guidelines - Describe the expected biomarker expression patterns for histologic types and grades of breast cancer - Discuss the evolving landscape of interpretation of HER2 assays - Recognize the indications and importance of multigene assays in breast cancer treatment decision making.